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Opinion statement
The mainstay of treatment for men with three or fewer non-castrate metastatic lesions
outside of the prostate remains morbid palliative androgen deprivation therapy. We
believe there is now a significant body of retrospective literature to suggest a survival
benefit if these men have radical treatment to their primary tumour alongside ‘metastasis-
directed therapy’ to the metastatic deposits. However, this regimen should be reserved to
high-volume centres with quality assurance programmes and excellent outcomes. Patients
should bemade clear as to the uncertainty of benefit for this multi-site treatment strategy,
and we await the publication of randomised controlled trials reporting in the next 5 years.
Introduction
Prostate cancer is the commonest cancer and the most
frequent cause of cancer death in Western men [1]. The
median survival for men presenting with metastatic dis-
ease is 42.1 months [2•]. Currently accepted treatment
consists of androgen deprivation therapy (ADT) follow-
ed by chemotherapy and novel agents once the ADT is
no longer effective. Treating metastatic disease is esti-
mated to cost healthcare systems US$20,000 per man
[3]. Oligometastatic disease can be defined as the devel-
opment of three or fewer non-castrate lesions outside of
the primary tumour [4••]. These can be bonemetastases
or in the soft tissue. The concept of oligometastatic
disease for all cancers is based around a stepwise pro-
gression whereby a cancer initially metastasises in a
limited way, before acquiring widespread metastatic be-
haviour [5]. In a range of solid tumours [6–8], it is
hypothesised that this intermediate step represents a
different biology compared to extensive metastatic dis-
ease, and therefore, it represents an opportunity to in-
fluence the rate of progression, and possibly even cure
the patient. It is thought that in oligometastatic states,
the true metastatic growth potential is limited. This may
be secondary to tumour microenvironments in the pri-
mary lesion remaining sufficiently hospitable that
evolutionary clonal pressure is low; therefore, cancer
cells that slough off the primary do not have the prop-
erties necessary to survive the circulation and invade
target organ sites effectively [9•]. This is contrasted with
systemic metastatic disease where the primary tumour
has created many undifferentiated aggressive clones that
actively migrate out of the primary tumour and have the
characteristics to survive and invade target organ sites.
The clinical implication of oligometastatic disease is that
treatment of metastases alongside the primary tumour
(if not already treated) could result in long-term survival
or cure [10, 11]. Treatment of oligometastatic disease
may also decrease disease-related morbidity and reduce
overall tumour burden. However, without randomised
controlled trials, it is very difficult to know if the
treatment of oligometastatic disease helps the patient.
The current literature in all cancer types is limited by
using varying definitions of oligometastasis, with a
variety of endpoints and at different levels of evi-
dence [9•]. With regard to prostate cancer, while
standard treatment remains long-term palliative an-
drogen deprivation treatment, there is emerging data
that treatment of the primary with stereotactic body
radiotherapy (SBRT) or even radical prostatectomy
may impact survival, slow symptomatic disease pro-
gression, and reduce the need for palliative surgical
intervention [12–15]. In this review, we evaluate the
three main treatment approaches for oligometastatic
prostate cancer—systemic therapy, treatment of the
primary tumour and metastasis-directed therapy.
Systemic Therapy
The standard treatment options and guidelines for prostate cancer (PCa) pa-
tients diagnosed with metastatic progression following primary treatment have
remained largely unchanged over the last decade [16••]. Androgen deprivation
therapy (ADT) remains the recommended treatment for men with any meta-
static disease [16••]. There is no level 1 evidence for or against a specific form of
ADT, with orchidectomy, LHRH analogue or antagonist all being acceptable
options. The exception remains patients with impending spinal cord compres-
sion for whomorchidectomy or LHRH antagonist are preferred [16••]. ADT can
be given alone or in combination with another anti-androgen such as
bicalutamide. Combined androgen blockade appears to show a small advan-
tage in systematic reviews when compared with monotherapy over more than
5 years [17, 18]. However, this advantagemust be weighed against the increased
side effects of combined treatment. ADT can also be given continuously or
intermittently. Intermittent androgen deprivation may offer better bone protec-
tion and a protective effect against metabolic syndrome, but the evidence is not
conclusive and most trials comparing the two have several limitations. A recent
review concluded that there is a small improvement in quality of life, but was
unable to prove non-inferiority [19]. Recently, data has emerged from the
STAMPEDE, CHAARTED andGETUG-15 trials that support the use of docetaxel
as a first-line treatment alongside ADT. It has been shown to improve survival
and delay the onset of castrate resistance [20••]. The STAMPEDE trial is also
evaluating the addition of enzalutamide to ADT in newly diagnosed metastatic
patients and the addition of both enzalutamide and abiraterone to ADT in the
same patient population [21]. The results of the trial may lead to further
combination therapies as first-line treatment. Despite a multitude of trials and
being the preferred treatment for decades, there is no evidence regarding the
outcomes of the sub-set ofmen who have oligometastatic disease as opposed to
the widespread systemic (polymetastatic) cohort. In men with widespread
systemic metastases, there is a very real risk of symptomatic bone pain, renal
failure, anaemia, pathological fractures and spinal compression. The early
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implementation of ADT has been shown to reduce these risks [22]. However, in
the setting of oligometastatic disease, where the likelihood of these clinical
manifestations is much lower, it may be that alternative treatments are more
appropriate. This is particularly significant when themorbidity and reduction in
quality of life that ADT causes is taken into account. Despite the evolving
thinking in oligometastatic disease, ADT + docetaxel remains the standard of
care in most centres.
Treating the Primary Site
Decreasing primary tumour burden, through cytoreductive or radical surgery,
radiotherapy or both together has been shown to improve survival in a number
of metastatic malignancies. Cytoreductive surgery has shown survival benefit in
colon [23], breast [24] and ovarian cancer [25]. Radical surgery to remove the
primary in the setting of metastases has been associated with improved survival
in glioblastoma [26], renal cell carcinoma [27] and colorectal cancer [28].
EORTC and Southwest Oncology Group studies have demonstrated that ne-
phrectomy plus systemic therapy offers a 13–36 % improvement in survival
when compared to systemic therapy alone [27, 29]. Similarly, ameta-analysis of
6885 women with advanced ovarian carcinoma found a median survival of
33.9 months in those treated with 975 %maximal cytoreductive surgery versus
22.7 months for those with ≤25 % cytoreduction [25]. The exact mechanism
underlying these results is not clear but there are a number of biologically
plausible explanations. The ‘soil and seed’ hypothesis postulates that tumour
cells require an appropriate microenvironment in which to engraft at the site of
metastasis. A number of studies have demonstrated a role for the primary
tumour in ‘priming’ the metastatic niche through the secretion of membrane-
bound vesicles such as exosomes which can transfer proteins and nucleic acids
to distant sites in advance of the engraftment of circulating tumour cells [30,
31]. Genetic interplay between primary and distant sites may play a role in the
development of metastatic prostate cancer. Interruption of this cycle by treating
radically or in a cytoreductive fashion may alter tumour biology and result in
depressed growth and/or limit the growth of future metastatic sites.
There are currently no reported prospective data regarding a survival benefit
for patients with metastatic prostate cancer who subsequently undergo treat-
ment of the primary tumour. However, a number of retrospective studies
support this strategy. A sub-group analysis of the SWOG 8894 trial found that
1286 men with metastatic prostate cancer showed a reduced risk of death for
those who had previously undergone radical prostatectomy compared to those
that had not [32]. Recent observational cohort studies from the US SEER
database and the Munich Cancer Registry found that men with metastatic
prostate cancer treated with radical therapy had higher 5-year survival than
those treated with systemic therapy alone [33•, 34•]. Sooriakumaran et al.
recently showed that at least 1206men in Sweden have been treated with initial
radical therapy (surgery or radiotherapy) for likely metastatic or
micrometastatic prostate cancer from 1996 to 2010 [35], and on further inter-
rogation of 18,352 cases found that men who underwent initial ADT without
radical therapy were approximately three times more likely to die of prostate
cancer than those that had radical therapy (manuscript in preparation). Very
recently published data from the Prostate Cancer data Base Sweden (PCBaSe)
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further supports these results by showing that men with very high-risk prostate
cancer for whom radical therapy has traditionally been seen as ineffective, have
substantially lower prostate cancer and all-causemortality when treated in units
with the highest exposure to radical treatment (surgery or radiotherapy) [36].
Increasingly, the evidence is suggesting patients with high-risk and metastatic
disease may benefit from radical or cytoreductive local therapy where patient
selection is appropriate and the unit they are treated in sufficiently experienced.
Treating the Metastases
Metastasis-directed therapy (MDT) is usually reserved for a sub-set of
patients with a limited number of metastases (typically three or fewer)
and therefore represents those patients defined as oligometastatic. The aim
is to control the cancer and slow down any further metastasis while
avoiding or delaying the toxicity associated with the use of systemic
therapies [37]. This is particularly true considering the detrimental effect
of ADT on general health and quality of life. MDT is commonly offered in
the setting of oligometastatic colorectal, sarcoma and renal cell carcinoma
[7, 38, 39]. Although no randomised controlled trials are available com-
paring MDT to no treatment, MDT is routinely offered based on the results
of promising case series and large patient registries [40]. The literature in
this sett ing refers to metachronous rather than synchronous
oligometastases, i.e. metastases developed some time after initial radical
therapy—in effect a treatment failure or an initial mis-staging. It is uncer-
tain whether results would be comparable in the setting of oligometastases
being detected at the time of the first diagnosis. Ost et al. carried out a
systematic review in 2015 that examined seven studies reporting on pa-
tients who had metachronous metastases with a Bcontrolled^ primary
(defined as previous curative treatment to the primary PCa) who received
MDT via surgical metastasectomy or non-palliative radiotherapy [4••].
Overall, 51 % of patients were progression free at 1–3 years after MDT
suggesting a promising approach for MDT. However, the low level of
evidence and the small number of studies do not allow extrapolation to
standard of care. A further analysis from Ost et al. in 2016 pooled the
individual patient data obtained from different institutions treating
metachronous oligometastatic PCa with stereotactic body radiotherapy
[41]. One hundred nineteen patients with 163 metastases were treated with a
median progression-free survival of 21 months. A dose response was demon-
strated with higher radiation doses leading to better rates of survival. The
implication from these results is that localised forms of cancer treatment might
be sufficient in these patients in order to delay systemic treatments until
progression to widespread metastases. There is no evidence that delaying ADT
in well-informed asymptomatic men with metastatic prostate cancer impacts
survival, and the EAU recommends this strategy where appropriate [16••].MDT
for prostate cancer recurrence appears promising andmay represent a paradigm
shift. However, its role in synchronous oligometastases is not clear, especially
regarding how this would be delivered alongside radical/cytoreductive therapy
for the primary tumour. The results of prospective comparative or randomised
trials are awaited before recommending changes to standard of care (Table 1).
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Future Work
In order for clinicians to safely and ethically offer patients surgery and/or
radiotherapy for oligometastatic prostate cancer, it is important to collect high
quality evidence, ideally from randomised controlled trials. The Surveillance or
metastasis-directed Therapy for OligoMetastatic Prostate cancer recurrence
(STOMP) trial is a phase II RCT being run from Belgium that will report in
2017 [42]. In patients with metachronous oligometastatic disease it aims to
compare MDT with active clinical surveillance. The hypothesis here is that MDT
will prolong the time until palliative ADT is required. The Conventional care or
Radioablation in the treatment of Extracranial metastases (CORE) trial running
at the Royal Marsden Hospital (London, UK) is examining whether the addi-
tion of stereotactic ablative SBRT delivered to metachronous oligometastases
can increase progression-free survival compared to standard care [43]. However,
it will not report until 2021. MD Anderson Cancer Centre is running a trial
comparing best systemic therapy (BST) alone versus BST plus radical prostatec-
tomy or radical radiotherapy directed at the primary in synchronous metastatic
disease, which includes polymetastatic disease also [44]. The primary outcome
is progression-free survival and it is due to report in 2018. Testing Radical
prostatectomy in men with oligometastatic prostate cancer that has spread to
the bone (TRoMbone) is a pilot RCT (Oxford, UK) that will randomise men
with synchronous oligometastatic disease to treatment as usual versus treat-
ment as usual plus radical prostatectomy [45]. It will recruit 50 patients and
report in 2018. Finally, the g-RAMPP trial based at the Martini-Klinik in Ger-
many has a similar protocol to TRoMbone but is attempting to recruit directly
to a full trial [46]. Its primary endpoint is prostate cancer-specific survival and
needs to enrol 452 patients with a planned report date of 2025.
Clearly, in the next few years, the evidence supporting how to best treat
oligometastatic disease will be strongly progressed and allow clinicians to better
advise their patients. Of note, the new imaging technology, for example, PSMA-
targeted PET agents, that are being rapidly adopted in some parts of the world is
Table 1. Novel treatment strategies for oligometastatic prostate cancer
Synchronous disease
Radical prostatectomy or prostate radiotherapy, or
Stereotactic body radiotherapy to the sites of oligometastases, or
Both of the above
Metachronous disease
Stereotactic body radiotherapy to the sites of oligometastases, or
Salvage prostate-directed therapies, or
Both of the above
In both settings, patients should be offered clinical trials where these are available, as none of the above treatment strategies are standard of
care
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likely to change the clinical workflow in terms of the way patients are staged.We
await with interest how these more accurate imaging strategies will impact on
the numbers of patients being diagnosed with oligometastatic disease, and how
it changes treatment practices.
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